Understanding FGL1's Role in Cancer Immunity and Developing New Immunotherapy
Elucidating the Role of Cancer-Associated FGL1 in Tumor Immunity and Developing FGL1-Guided Anti-LAG-3 Cancer Immunotherapy
This project aims to find new ways to boost the body's immune response against cancer by targeting a protein called FGL1.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11126873 on NIH RePORTER |
What this research studies
Many cancer patients don't respond well to current immune therapies that block certain "checkpoints" on immune cells. This project focuses on a different checkpoint, LAG-3, and a newly discovered protein called FGL1 that interacts with it. Researchers believe that blocking FGL1 could help unleash the immune system to fight tumors more effectively. They are working to understand how FGL1 affects immune cells and to develop new treatments that specifically target this interaction.
Who could benefit from this research
Good fit: Patients with various types of cancer, particularly those who have not benefited from current immune checkpoint therapies, might eventually be candidates for treatments developed from this research.
Not a fit: Patients whose cancers do not involve the FGL1-LAG-3 pathway may not receive direct benefit from this specific approach.
Why it matters
Potential benefit: If successful, this work could lead to new immunotherapy options for cancer patients, especially those who haven't responded to existing treatments.
How similar studies have performed: While LAG-3 blocking antibodies are showing some promise in clinical trials, the specific targeting of FGL1 as a major ligand for LAG-3 is a novel and less explored approach.
Where this research is happening
New York, United States
- New York University School of Medicine — New York, United States (Active)
Researchers
- Principal investigator: Wang, Jun — New York University School of Medicine
- Study coordinator: Wang, Jun
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.